Clinical trial TULIP
A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer / TULIP
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Synthon Biopharmaceuticals |
EudraCT Identifier | 2017-001994-18 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03262935 |
Inclusion criteria | HER2 positive/ RECIST 1.1/ After HER2 targeting treatment |
Last update |